Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
View Top Employees from Cerevel Therapeutics| Website | https://www.cerevel.com |
| Ticker | CERE |
| Revenue | $63 million |
| Funding | $350 million |
| Employees | 340 (340 on RocketReach) |
| Founded | 2018 |
| Address | 222 Jacobs Street Suite 200, Suite 200, Cambridge, Massachusetts 02141, US |
| Phone | (844) 304-2048 |
| Technologies |
JavaScript,
HTML,
Twitter
+64 more
(view full list)
|
| Category | Pharmaceutical Manufacturing, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Pharmaceutical, Health Care, Therapeutics |
| Competitors | Acadia Pharmaceuticals Inc., Denali Therapeutics, Intra-Cellular Therapies, Sage Therapeutics, Vanda Pharmaceuticals |
| SIC | 87, 873 |
| NAICS | 325, 541, 32541, 3254, 54, 32 |
Looking for a particular Cerevel Therapeutics employee's phone or email?
Cerevel Therapeutics Questions
The Cerevel Therapeutics annual revenue was $63 million in 2023.
Susan Altschuller is the CFO of Cerevel Therapeutics.
340 people are employed at Cerevel Therapeutics.
Cerevel Therapeutics is based in Cambridge, Massachusetts.
The NAICS codes for Cerevel Therapeutics are [325, 541, 32541, 3254, 54, 32].
The SIC codes for Cerevel Therapeutics are [87, 873].
Top Cerevel Therapeutics Employees
-
55+
-
25+
-
45+
-
35
-
View
Edward Keysor
Vice President, Program and Portfolio Management at Cerevel Therapeutics
Cambridge, MA, US35+
Related Companies
